JPRN-UMIN000004188已完成未知
A prospective, randomized controlled trial comparing alendronate and alendronate plus alphacalcidol therapy in patients with steroid-induced osteoporosis accompanied with interstitial pneumonias - Steroid-induced osteoporosis accompanied with interstitial pneumonias
agasaki University School of Medicine0 个研究点目标入组 60 人开始时间: 2010年9月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) The patients who have severe complications (2) The patients who have the diseases of bone metabolism (3) The patients who were administered steroid therapy within a year (4) The patients who are administered therapy affecting bone metabolism (5) The patients who have fracture or scoliosis at 3rd to 5th lumbar (6) The patients who have impaired renal function (Cr > 1.5mg/dl) (7) The patients who are contraindicated to take alendronate or alphacalcidol (8) The patients who are pregnant (9) The patients who attended clinical trials within three months
研究者
相似试验
尚未招募
4 期
A clinical trial to study the effect and safety of intravenous cyclophosphamide and tacrolimus in children with steroid resistant nephrotic syndromeCTRI/2008/091/000215il130
尚未招募
不适用
Study to compare an injection given in lower back with injections given in outer layer of abdomen in children undergoing lower abdominal surgery for pain scores.CTRI/2017/12/010988Post graduate institute of medical education and research
尚未招募
2 期
A prospective randomized controlled trial comparing antecolic route and retroclic route with Roux-Y reconstruction after distal gastrectomy.Gastric cancerJPRN-UMIN000012062agoya University Graduate School of Medicine120
已完成
4 期
A Prospective Randomized Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular CarcinomaCancer - LiverHepatocellular carcinomaACTRN12608000577314Eastern Hepatobiliary Surgery Hospital100
已完成
3 期
Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19)IRCT20200128046294N2Digestive Disease Research Institute70